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Abstract
Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to
sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved?
Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional
chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs,
drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled
drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic
erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential
for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show
that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to
efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and
the dose required is 10 time less than that needed with conventional therapy.
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Introduction
The success of any medical treatment depends not only upon the
pharmacokinetic/pharmacodynamic activity of the therapeutic
agent, but to a large extent, on its bioavailability at the site of action
in the human system [1–4]. In the past, alternative pharmaceutical
formulations of anti-cancer agents have been investigated in order to
improve conventional chemotherapy treatment. In conventional/
current therapy oral tablet, capsule and injectable formulations are
used for anti-cancer drugs delivery. These formulations areassociated
with problems like severe toxic side effects on healthy organs,
difficulties in clinical administration, drug resistance and limited
accessofthedrugtothetumorsitessuggestedtheneedtofocusonsite
specific controlled drug delivery systems.
Drug delivery systems (DDSs) such as lipid- or polymer-based
nanoparticles have been designed to improve the pharmacological
and therapeutic properties of drugs administered parenterally. The
majority of the DDS currently approved for parenteral administra-
tion falls into the category of liposomal or lipid-based formulations or
therapeutic molecules linked to polyethylene glycol (PEG) [5–7].
Although drug solubility may not be a limiting factor for systems such
as polymer-drug conjugates, in which the drug is chemically linked to
the carrier, it can be an important consideration in liposomal DDS.
Carrying capacity of liposomes is not efficient for very large
therapeutic molecules such as proteins, particularly when small
liposome diameters are desirable for reasons of biodistribution.
Biodegradable nano/microparticles of poly(D,L-lactide-co-glycolide)
(PLGA) and PLGA-based polymers are widely explored as carriers
for controlled delivery of macromolecular therapeutics such as
proteins, peptides, vaccines, genes, antigens and growth factors.
Literature cites many advantages and drawbacks of PLGA and
PLGA-based delivery systems for delivering macromolecular drugs
[8,9]. Drug encapsulation, particle size, additives added during
formulation, molecular weight, ratioof lactide to glycolide moieties in
PLGA and surface morphology could influence the release
characteristics [10]. PLGA has a negative effect on protein stability
during the preparation and storage, primarily due to the acid-
catalyzed nature of its degradation [11]. In addition, processing
conditions used in the manufacturing of PLGA drug delivery vehicles
have detrimental effects on certain protein secondary structures [12].
In the past few years, cell-based delivery systems have also been
developed. The use of cells as therapeutic carriers has developed as a
distinct concept and delivery method [13–17]. Cell-based vehicles are
particularly attractive for delivery of bio-therapeutic agents that are
difficult to synthesize, have reduced half-lives, limited tissue
penetration or are rapidly inactivated upon direct in vivo introduction.
Asa matterof facts, the cell-based deliverysystem possessesa number
of advantages including prolonged delivery times, targeting of drugs
to specialized cell compartments and biocompatibility. The use of a
physiological carrier to deliver therapeutics throughout the body to
both improve their efficacy while minimising inevitable adverse side
effects, is an appealing perspective that can be applied in many
clinical settings. The behaviour of blood cells, as a delivery system for
several classes of molecules (i.e., proteins, including enzymes and
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glucocorticoidanalogues),has been studied extensively as they possess
several properties, which make them unique and useful carriers [18–
20]. In the context of extracorporeal pharmacotherapy, the most
promising approach is the use of autoerythrocytes which possess
unique morphological and physiological characteristics. Application
of erythrocytes as containers for various drugs decreases the risk of
side effects and pathologic immune reactions against encapsulated
agents and, moreover, it allows the modification of their pharmaco-
kinetic and pharmacodynamic properties for reducing doses and
intervals between them. The efficacy and safety of pharmaceutical
agents introduced into erythrocytes have been confirmed in
numerous in vivo studies [20]. The magnetic erythrocytes, resulting
from the co-encapsulation of the drugs with some ferrofluids such as
cobalt–ferrite and magnetite, have been reported to direct the
encapsulated drug predominantly to the desired sites of the body by
means of an external magnetic field [21–23]. Applying ultrasound
waves in the region where magnetic erythrocytes accumulate can
induce vehicle destruction and the release of a drug at the organ or
tissue level [24,25]. In addition to drug targeting, this method has
been evaluated for induction of local ischemia in tumors, which may
consequently help to promote tumor remission because of reduced
local blood flow [22]. However, the potential ability of cell carriers to
provide site-specific or targeted delivery of therapeutics has yet to be
fully explored. Development of cell targeting strategies will further
advance cell vehicle applications, broaden the applicability of this
delivery approach and potentiate therapeutic outcomes.
In an attempt to improve the targeting and the efficient release of
therapeutic compounds at the intra-cellular level of target cells, we
have developed a novel magnetic field-controlled erythrocyte-based
drug delivery system. Attaching a viral spike fusion glycoprotein on
the erythrocytes’ membrane and encapsulating superparamagnetic
nanoparticles and drug into erythrocytes, we have produced new
erythrocytes-based drug delivery system, the erythro-magneto-HA
virosomes, which have the potential for magnetic-controlled site-
specific localization and highly efficient fusion capability with the
targeted cells. The presence of viral fusion glycoprotein makes the
application of ultrasound wave unnecessary for inducing ‘‘vehicle’’
destruction for the release of therapeutic compounds at the target
site. Here we show how the erythro-magneto-HA virosomes behave
somewhat akin to an enveloped virus in their ability to invade host
cells. These engineered erythrocytes are able to fuse with the
cytoplasmatic membrane of target cells in a very short time and
release the magnetic nanoparticles and therapeutic compound
inside these cells. The total amount of the anticancer drug 5-Aza-2-
deoxycytidine has a therapeutic effect 10 times less than that of
standard therapy, suggesting that this new drug delivery system may
be able to reduce cytotoxic effects of drugs by increasing the
bioavailability of therapeutic compounds at the site of action and
improving pharmacokinetics. This new erythrocyte-based drug
delivery system can potentially be applied in many clinical settings,
includingneoplasticpathologies, pathologiescausedbytheinfection
of a human or animal viruses and cardiovascular diseases.
Materials and Methods
Influenza Virus growth and isolation of Hemagglutinin
(HA) glycoprotein
Influenza virus obtained from the allantoic liquid of 10-days-old
embryonatedeggs(eggswere obtainedfromchickenfactory inRome,
Italy) was pelleted by ultracentrifugation and the pellet was
resuspended in octa(ethyleneglycol)-n-dodecyl monoether (C12E8)
and left overnight to allow for complete solubilisation of the viral
membrane. The suspension was carefully homogenised and ultra-
centrifugated to pellet down the viral nucleocapsids. Next, the
virosome suspension (supernatant containing the HA protein) was
purified by ultracentrifugation on a discontinuous sucrose-gradient
(50% and 10% of sucrose). At the interface of the sucrose layers, the
HA glycoprotein concentrates. After removal of this layer, the HA
has been dialysed against buffer and sterilized by filtration.
Erythrocytes lysis and incorporation of HA glycoprotein,
super paramagnetic nanoparticles and 5-Aza-2-dC drug
Human Red Blood Cells (RBCs) were obtained from blood of
healthy donors by centrifugation at 1700 rpm for 10 min at 4uC.
Freshly collected RBCs were washed twice in physiological
phosphate-buffer saline (1X PBS) (1.37 M NaCl, 57 mM KCl,
54 mM Na2HPO4,4 5m MK H 2PO4 pH 7.4).
2610
9 RBCs were lysed in 300 ml lysis buffer (10 mM TRIS,
0.1 mM EDTA, 1 mM MgCl2 at pH 7.2) for 60 minutes at 0uC.
The isotonicity was then restored by adding 65 ml of 1 X resealing
buffer (1.37 M NaCl, 57 mM KCl, 54 mM Na2HPO4,4 5m M
KH2PO4, 15 mM MgCl2 pH 7.4), supplemented with 0.1 mg of
100 nm red-labelled superparamagnetic nanoparticles (nano-
screenMAG, Chemicell Company), 1 mg HA influenza viral spike
glycoprotein, and 0.38 or 30.5 mg 5-Aza-2-dC (Sigma-Aldrich, St
Louis, MO, USA).
The suspension was incubated for 45 minutes at 37uC under
mild agitation. Sealed RBCs (ghosts), containing HA fusion
protein on lipid membrane and both 5-Aza-2-dC and super-
paramagnetic nanoparticles inside (erythro-magneto-HA viro-
some), were collected by centrifugation at 10,000 rpm for 15
minutes at 4uC. The erythro-magneto-HA virosomes were washed
twice with 1X PBS by centrifugation at 9,000 rpm for 15 minutes
at 4uC and resuspended in 1X PBS containing 1% FCS.
Kinetics of Erythro-magneto-HA virosomes fusion with
HeLa cells: Spectrofluorimeter analysis
Erythro-magneto-HA virosomes were prepared as described
above and were labelled by adding Octadecyl Rhodamine (R18).
The Erythro-magneto-HA virosomes/R18 loaded were added to
HeLa cells. Total lipid in erythro-magneto-HA virosomes/R18
was quantified by the amount of Octadecyl Rhodamine (R18) in
their membrane, based on the fact that R18 accounts for 15% of
the total weight of lipids on it. The erythro-magneto-HA-
virosomes/R18 were solubilized by adding 0.1% (final concentra-
tion) Triton X-100 in PBS, and the fluorescence of R18 (excitation
at 560 nm and emission at 590 nm) was measured using an aliquot
of the solution with a spectrofluorometer Perkin Elmer 650-40),
calibrated with R18 standard solutions containing 0.1% Triton X-
100. The degree of R18 self-quenching in each erythro-magneto-
HA virosomes was examined by comparison of R18 fluorescence
before and after solubilization of the erythro-magneto-HA
virosomes with 0.1% Triton X-100 in PBS. Erythro-magneto-
HA virosomes were added to HeLa cells. The kinetic of erythro-
magneto-HA virosomes fusion with HeLa cells was calculated as
% of R18 fluorescence dequenching (FDQ) using 560 and 590 nm
as excitation and emission wavelengths respectively. As control we
prepared R18-labeled magnetic erythrocytes without reconstituted
HA fusion protein. The kinetic of fusion of these magnetic
erythrocytes with HeLa cells was also analyzed.
HPLC analysis of 5-Aza-2-dC incorporation in Erythro-
magneto-HA virosomes
Chemicals and solutions. 5-Aza-2-deoxycytidine (5-Aza-2-
dC, Decitabine) was purchased from Sigma-Aldrich (St Louis,
MO, USA). Ammonium acetate was from Carlo Erba (Milan,
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(Walkerburn, UK).
HPLC analysis of Erythro-magneto-HA virosomes
containing decitabine. 2610
9 erythro-magneto-HA virosomes
were incubated with 200 ml lysis buffer to release the incorporated 5-
Aza-2-dC drug and centrifuged at 10,000 rpm for 15 minutes at 4uC.
ThesupernatantwasrecoveredandusedforHPLCanalysisorstored
in a 280uC freezer until analysis.
Stock standard solutions of decitabine at concentration of 114,
228, 456 and 1140 ng/ml, were prepared individually in water
solution or lysis buffer and stored at 280uC until analysis.
The peak area ratio of sample/5-Aza-2-dC (decitabine,
standard) was used for quantitation. The limit of detection
(LOD) was defined as three times the signal-to-noise ratio. The
lowest limit of quantitation (LLOQ) was defined as the lowest level
of analyte that could be reliably detected and reproducible with a
precision of #20% and accuracy of 80–120%.
Instrumentation. The HPLC system comprised of a Dionex
(Sunnyvale, CA, USA) 3000 Ultimate series LC connected to a
linear ion Trap LTQ-Orbitrap (Thermo Fisher Scientific, USA)
mass spectrometer, equipped with an electrospray ion source. Data
were acquired and processed with Excalibur 2.1 software.
Compounds were separated on a Gemini C18 (150 mm-2.0 mm
I.D.) and 3 mm particle size (Phenomenex, Torrance, CA, USA)
protected by a Phenomenex Gemini C18 (4.0 mm—2.0 mm I.D.)
and 3 mm particle size guard cartridge. The HPLC method used
gradient elution; mobile phase solvent A was water with 0,1%
formic acid and mobile phase B was acetonitrile with 0,1% formic
acid. The initial mobile phase composition of 92% solvent A and
8% solvent B was maintained for 2 min. Between 2 and 9 min the
percentage of mobile phase B was increased to 35% and then back
to initial the mobile phase composition within 0,1 min, with a total
time of 14 min. The column was set at a flow rate of 0.2 ml min21
and a temperature of 36uC. Sample volume of 10 ml was used for all
LC–MS experiments. The mass spectrometer was operated in
positive electrospray mode. The capillar temperature was 275uC
and the spray voltage 4.5 kV was used.
Tumor HeLa cells treatments
Human HeLa cells were purchased from the American Type
Culture Collection (Rockville, MD).
The cells were maintained in DMEM medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, at split ratio of
1:4 twice a week.
For treatments, 3 ml of cells at a density of 5610
5 were seeded
in 6-well microtiter plates. Two sets of experiments were run in
parallel for both Confocal Laser Scanning Microscopy (CLSM)
and FACS analysis. For CLSM analysis, on the bottom of the
culture plates there were placed glass coverslips on which the cells
were let grow.
After 24 hours, the culture medium was changed with media
containing 2,5 mM 5-Aza-2-dC alone or 1610
9 5-Aza-dC-loaded
erythro-magneto-HA virosomes or buffer in which the erythro-
magneto-HA-virosomes were resuspended (supernatant, control-
2). After 30 min, 1, 6, 24, 48 and 96 hours of incubation, treated
and untreated (control-1) cells were analyzed by CLSM and FACS
analysis.
Confocal Laser Scanning Microscopy (CLSM) analysis of
fusion events of erythro-magneto-HA virosomes with
tumor cells
Tumor cells grown on slides in presence of 5-Aza-2-dC-loaded
erythro-magneto-HA virosomes were washed in 1X PBS buffer
and fixed with 4% paraformaldehyde. Cell nuclei were counter-
stained with DAPI and mounted in antifade medium. Fluores-
cence and bright-field images were obtained by a Leica TCS SP5
inverted microscope system, equipped with five lasers emitting
from the UV to the visible (405 Diode, Argon, HeNe 543, HeNe
594 and HeNe 633). The DAPI fluorescence was detected at
excitation of 405 nm and emission of 454 nm while the red
fluorescence of superparamagnetic nanoparticles at excitation of
543 nm and emission of 613 nm.
Cytofluorimetric analysis (FACS analysis)
FACS analysis was carried out on HeLa cells treated with
2,5 mM 5-Aza-dC or 1X 10
9 5-Aza-2-dC-loaded erythro-magne-
to-HA-virosomes and compared to those untreated (control-1)
after 24, 48 and 96 hours of culture. FACS analysis was also
carried out on HeLa cells treated with buffer in which the erythro-
HA-virosomes were resuspended to check the absence of
unincorporated 5-Aza-2-dC drug (control-2). Treated and un-
treated cells were fixed in ethyl alcohol and the nuclei were stained
with 10 mg/ml of propidium iodide and incubated with 100 mg/ml
of RNase for 1 hour at 37uC. The nuclear DNA content, which
discriminates the cell cycle phases, was determined by flow
cytometry using the Becton–Dickinson FACScan CentroII.
Ethics statements
For the present study we did not need ethic approval since the
work was not involving human nor animal studies.
The present study was performed without utilizing donors from
human volunteer material, human blood was obtained from
transfusional bag from the blood bank, for those reasons we did
not need informed consent.
Results
Behaviour of erythro-magneto-HA virosomes
A new erythrocyte-based drug delivery system described here is
potentially capable of delivering drugs to target tissues increasing
the bioavailability of therapeutic compounds at the site of action
leading to a better therapeutic effect with minimal side effects.
Human erythrocytes were isolated from the blood of a healthy
donor and treated with a hypotonic solution to induce the opening
of membrane pores and release hemoglobin. A mix containing
Hemagglutinin (HA) viral spike fusion proteins, fluorescent
superparamagnetic nanoparticles and the therapeutic compound
was added during the resealing of ‘‘ghost’’ erythrocytes. Due to the
high affinity for membranes, hemagglutinin binds to the cytoplas-
matic membrane of erythrocytes while magnetic nanoparticles
(green fluorescence) and drug penetrate through pores into
‘‘ghost’’ erythrocytes (Fig. 1).
To verify the effective trapping of 5-Aza-2-dC (Decitabine) in
our erythrocyte-based drug delivery system and to quantify the
yield of therapeutic compound encapsulated, we performed HPLC
analysis (Fig. 2). Liquid chromatography/tandem mass spectrom-
etry quantification method (QTOF/MS) has been used in order to
quantify and identify the 5-Aza-2-dC isoforms and their
decomposition products under physiologic conditions of pH and
temperature as previously described [26,27].
In Figure 2 A and B, the peaks of both 5-Aza-2-dC (standard)
and 5-Aza-2-dC loaded in 2610
9 erythro-magneto-HA virosomes
are shown. The samples were monitored in positive mode,
resulting in species of 1 mass unit higher than the neutral
molecules. Data were visualized by extracting the ion chromato-
grams at m/z=229. In the standard solution (Fig. 2 A) two peaks
corresponding to both single charged b- (I) and a-forms (II) of 5-
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evident in addition to 5-Aza-2-dC b- and a-forms (I and II). This
peak corresponds to a guanylurea derivate (III) (m/z=219). As
previously shown, extracted ion chromatograms at m/z=219
(guanylurea derivatives, single charged monomeric species) are not
unique as an identifier of guanylurea derivatives as compounds
with m/z=229 also produce fragments with m/z=219 when
visualized by mass spectrometer [28]. b-forms (I) of 5-Aza-2-dC
become hydrated at the C-6 position and the ring-opens to
produce a ring-open-formylated derivative, followed by loss of
formic acid, which then produces a guanylurea derivative (III).
Deformylation of any of the ring-open formylated derivatives into
the guanylurea derivatives (III) results in loss of the H-6 proton as
formic acid. The retention times (RT) as well as the area values
(AA) for each peak are shown in Figure 2 A and B.
To quantify the amount of 5-Aza-2-dC contained in the
erythrocyte-based delivery system, 10 ml of each standard and
sample were injected in HPLC. Different concentrations of
standard, spanning from 0,114 ng/ml (0,5 mM) to 1,14 ngml
(5 mM) of 5-Aza-2-dC, were prepared and the peak area of each
10 ml sample was calculated by HPLC. The peak area values of
standards were put in relation to the ng of 5-Aza-2-dC and a
calibration curve was designed (Fig. 2 C). Figure 2 A shows the
area value (AA: 660.834) detected by HPLC corresponding to
1,14 ng (0,5 mM) of 5-Aza-2-dC standard solution. Different
samples of erythro-magneto-HA virosomes were prepared and
different amounts of 5-Aza-2-dC, spanning from 0,5 ng/ml
(2,5 mM) to 42 ng/ml (200 mM), were added during the resealing.
To assess the effective amount of 5-Aza-2-dC entrapped in
erythrocytes for each preparation, 2610
9 erythro-magneto-HA
virosomes were lysed in 200 ml lysis buffer. The total amount of
drug incorporated into 2610
9 erythro-magneto-HA virosomes was
3,6 ng or 360 ng when 2,5 mM or 200 mM of 5-Aza-2-dC were
added to erythrocytes during resealing, respectively (Fig. 2 C).
Therefore, the efficiency of incorporation for each sample was
approximately 1%.
To test the effective incorporation of Hemagglutinin (HA) on
erythrocyte membranes and its fusion activity, we evaluated the
kinetics of fusion of our engineered erythro-magneto-HA viro-
somes with target cells. Octadecyl Rhodamine (R18) labeling was
used to determine the fusion of erythro-magneto-HA virosomes
with HeLa cells. Fusion has been reported as % of R18
fluorescence dequenching (FDQ) using 560 and 590 nm as
excitation and emission wavelengths, respectively. The fusion of
erythro-magneto-HA virosomes with HeLa cells starts after a very
short period (few minutes) and the percentage of fusion
exponentially increases with time (Fig. 3). In contrast, magnetic
erythrocytes without Hemaglutinin (HA) do not show fusion
activity with HeLa cells. These data indicate that the viral spike
glycoprotein (HA) purified from influenza virus and reconstituted
in magnetic erythrocyte vehicles maintains its fusogenic properties
with the cytoplasmatic membranes of the target cells and confers
on magnetic erythrocytes the ability to fuse with target cells.
Effect of Decitabine-loaded erythro-magneto-HA
virosomes on tumor cells
To verify the efficiency and efficacy of our erythrocyte-based
drug delivery system, we treated HeLa tumor cells either with 5-
Aza-2-dC alone or encapsulated into erythro-magneto-HA
virosomes. 5610
5 tumor cells were treated either with 1.800 ng
of 5-Aza-2-dC (2,5 mM), a concentration shown to have
therapeutic effect in vitro, or with 1610
9 erythro-magneto-HA
virosomes containing 10 times less 5-Aza-2dC (180 ng).
The uptake to the target cell and delivery of the therapeutic
compound into the cytoplasm of tumor cells is shown in Fig. 4.A t
very short times (from 30 min to 1 hour) it is still possible to
distinguish engineered erythrocytes which start to blend with target
cells (Fig. 4 A and B). After6 hours most of the targetcells show the
erythro-magneto-HA virosomes within the cytoplasm (Fig. 4 C).
The erythro-magneto-HA virosome, internalized inside the ‘‘host’’
cell, looks like a viral endosome. The membrane of erythro-
magneto-HA virosomes starts to fuse with the membrane of the
target cell between 12 and 24 hours, whereupon the fluorescent
nanoparticles and the drug start to diffuse inside the tumor cells.
After 24 hours all the tumor cells showed a strong fluorescence in
the cytoplasm and some have the typical morphology of early
apoptosis. At 96 hours most of tumor cells show the characteristic
micronuclei morphology of late apoptosis (Fig. 4 D).
The efficacy of 5-Aza-2-dC reconstituted into erythro-magneto-
HA virosomes in promoting apoptosis relative to free drug is
shown in Figure 5. HeLa cells untreated (control) and treated
with 1800 ng 5-Aza-2-dC or with 1610
9 erythro-magneto-HA
virosomes containing 180 ng of Decitabine were analyzed by
FACS. As controls to assess possible toxic effects of the vehicle
alone on cells, HeLa cells were cultured also in presence of the
buffer solution in which 5-Aza-2-dC-loaded erythro-magneto-HA
virosomes were suspended (supernatant) and with erythro-
magneto-HA virosomes encapsulating only the fluorescent mag-
neto-nanoparticles.
After 96 hours only 12,6% of cells treated with 1800 ng of free
5-Aza-2-dC appear apoptotic compared with 96% of cells when
cells are treated with 180 ng in erythro-magneto-HA virosomes.
Moreover, at 24 hours significant apoptosis is seen with the drug
delivery system while virtually no effect is observed for drug alone.
These observations suggest that erythro-magneto-HA virosomes
delivery system increases the anti-neoplastic effect of 5-Aza-2-dC
through enhancement of drug bioavailability. Neither the
supernatant, where the 5-Aza-2-dC-loaded erythro-magneto-HA
virosomes are suspended, nor erythro-magneto-HA virosomes
containing only fluorescent nanoparticles have an effect on cell
proliferation, demonstrating that our erythrocyte-based drug
delivery system itself has not toxic effect on cells. Together these
results suggest that this new erythrocyte-based drug delivery
system has the potential to increase the efficiency and efficacy of
therapeutic compounds.
Figure 1. Engineered Erythrocytes. Confocal Laser Scanning
Microscopy (CLSM) images of erytro-magneto-HA virosomes encapsu-
lating 100 nm fluorescence-labelled superparamagnetic nanoparticles
(green) and 5-Aza-2-dC.
doi:10.1371/journal.pone.0017132.g001
Engineered Magnetic Erythrocytes Delivery System
PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e17132Figure 2. HPLC/QTOF quantitative analysis of 5-Aza-dC. (A) Peaks of 1,14 ng 5-Aza-dC (standard). (B) Peaks of 5-Aza-dC encapsulated into
2610
9 erythro-magneto-HA virosomes. RT: retention time; AA: peak area counts. (C) Calibration curve of 5-Aza-dC. The peak area values of standards
were put in relation with the ng/10 ml of 5-Aza-2-dC sample ran. Standard solutions used were 1,14, 2,28, 4,56 and 11,40 ng 5-Aza-dC (black
rhombuses). Grey triangles show the 5-Aza-dC concentrations found within the two erythro-magneto-HA virosomes samples used in in vitro
experiments.
doi:10.1371/journal.pone.0017132.g002
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Cytotoxic chemotherapy or radiotherapy of cancer is limited
by serious, sometimes life-threatening, side effects because of the
lack of specificity to target cells alone. One strategy to improve
specificity is to encapsulate the therapeutics into a drug delivery
system capable of directing therapeutic compounds to a target
site.
Carrier erythrocytes have been evaluated for their use in drug
delivery in humans proving their safety and efficacy [29].
Erythrocyte-based delivery of new and conventional drugs is
thus experiencing increasing interests in drug delivery and in
managing complex pathologies, especially when side effects could
become serious issues [13,19,30]. Recently, erythrocytes have
been used to encapsulate the antibiotic amikacin, and a sustained
release from loaded erythrocytes over a 48 hours period was
demonstrated, suggesting a potential use of the erythrocytes as a
slow systemic-release system for antibiotics. The administration of
amikacin by loaded erythrocytes in rats leads to significant
changes in the pharmacokinetic behavior of the antibiotic
[31,32]. The erythrocyte-based drug delivery system presents
various advantages: it is especially efficient in releasing drugs in
the circulation for long period of time (weeks), erythrocytes have a
large trapping capacity, are easily processed and have capability
to accommodate traditional and biologic drugs [18,30]. Eryth-
rocytes loaded with ferromagnetic colloid compound can be
magnetically driven at the target organ/tissue by means of an
external magnetic field [21–23,33] Finally, the availability of an
apparatus that permits the encapsulation of drugs into autologous
Figure 3. Kinetic Fusion assay. The 5-Aza-2-dC-loaded erythro-
magneto-HA virosomes were labelled with Octadecyl Rhodamine (R18)
and incubated with HeLa cells. Fusion has been reported as % of R18
fluorescence dequenching (FDQ) using 560 and 590 nm as excitation
and emission wavelengths respectively. RBC: 5-Aza-2-dC-loaded mag-
netic erythrocytes without reconstituted HA fusion protein (Control);
RBC-HA: 5-Aza-2-dC-loaded erythro-magneto-HA virosomes.
doi:10.1371/journal.pone.0017132.g003
Figure 4. Confocal Laser Scanning Microscopy (CLSM). In the left is schematized the timing and mechanism of action of the erythro-magneto-
HA virosomes, encapsulating 100 nm fluorescence-labelled magnetic nanoparticles (green) and 5-Aza-2-dC. In the right are shown CLSM images of
erythro-magneto-HA virosomes (green) after 30 minutes (A), 1 hour (B), 6 hours (C), 24 and 96 hours (D) of incubation with HeLa cells highlighted by
DAPI staining (blue). (CTRL) Untreated HeLa cells (control).
doi:10.1371/journal.pone.0017132.g004
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settings and competitive with respect to other drug delivery
systems [34].
In the present work we point out a new erythrocyte-based drug
delivery system, the erythro-magneto-HA virosome, where the
human erythrocytes have been engineered with both viral spike
fusion proteins and superparamagnetic nanoparticles. This drug
delivery system, thanks to its both magnetic and high efficient
fusion properties, can be used to specifically drive the drug or pro-
drug at target organ or tissue and release the therapeutic
compound directly inside the target cells thus improving the
efficiency and efficacy of therapy.
The efficiency of our erythrocyte-based delivery system based
on the possibility to magnetically drive and concentrate the
therapeutic compounds in a site-specific manner by applying
physical method, the static magnetic field, at level of target tissue/
organ, as previously described [21–23,33]. In this way it is possible
to control the distribution and location of the drug delivery system
because of the magnetic properties of nanoparticles encapsulated
inside the red blood cells. Furthermore, the efficiency of our
system also depends on its high capability to fuse with the target
cells through the binding of hemagglutinin (HA) viral spike fusion
protein to the target cell membrane thus improving the efficacy of
therapy. Kinetic fusion assay data outlined here indicate that the
Figure 5. FACS analysis of HeLa cells after (A) 24 h, (B) 48 h and (C) 96 h treatments. Ctrl (control) untreated cells; Aza: cells treated with
1800 ng (2,5 mM) of 5-Aza-2-dC; Erythro Aza: cells treated with erythro-magneto-HA virosomes containing 180 ng of 5-Aza-2-dC; Erythro:
unloaded 5-Aza-2-dC erythro-magneto-HA virosomes; Supernatant: cells treated with buffer where the erythro-magneto-HA virosomes were
resuspended (control 2).
doi:10.1371/journal.pone.0017132.g005
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influenza virions and reconstituted in magnetic erythrocyte
vehicles, maintains its fusogenic properties thus determining the
integration of the delivery system with the cytoplasmatic
membranes of target cells notwithstanding the dimension (8
micron) of the erythro-magneto-HA virosomes.
Our observations indicate that the engineered erythrocytes dock
onto the target cell through the interaction of the HA protein with
sialic acid residues on the surface of the target cells. The
integration of the erythrocytes into target cells presumably occurs
through receptor-mediated endocytosis. The erythrocytes presum-
ably enter endosomes where subsequent fusion of erythrocyte and
endosomal membranes releases drug and magnetic particles into
the cytoplasm. In this manner, the drug encapsulated in the
‘‘ghost’’ erythrocytes does not undertake its pharmacological and
toxicological function until it reaches the target cells. This is of
considerable importance in the case of certain drugs with short
half-life or with major toxicity such as anti-neoplastic drugs.
Here we show that the pharmacological and toxicological
function as well as half-life of one test drug, 5-Aza-2-dC, are
preserved and enhanced by our erythrocyte-based delivery system.
5-Aza-2-dC is effective against myelodysplastic syndromes and
various types of leukaemias [35–37] and is in clinical trial for other
human cancers [38,39]. The primary mechanism for the activity
of 5-Aza-2-dC is believed to be through inhibiting methyltrans-
ferases involved in epigenetic modifications [40] 5-Aza-2-dC also
has demonstrated toxicity [41] and some reports suggest that it
could be mutagenic [42]. The 5-Aza-2-dC is a pro-drug that
requires metabolic activation by deoxycytidine kinase to exert its
function as anti-cancer drug [35]. In human, 5-Aza-2-dC has a
short half-life of 15 to 25 minutes due to rapid inactivation by liver
cytidine deaminase. The instability of 5-Aza-2-deoxycytidine
under physiological conditions creates a significant challenge to
its use in humans. It has previously been reported that a plethora
of compounds are generated during the chemical decomposition of
5-Aza-2-dC at physiological pH and temperature [28,43]. It has
been shown that 5-Aza-2-dC is converted into its corresponding
ring-open-formylated derivates followed by irreversible deformyla-
tion into the guanylurea derivates. It has been suggested that these
ring-open products block DNA polymerases and create potentially
lethal lesions [44]. The guanylurea derivates have the potential to
mispair during replication thus determining an accumulation of
mutations into DNA. The chromatography/tandem mass spec-
trometry quantification method (see the QTOF/MS analysis) is
used here to quantify and identify the 5-Aza-2-deoxycytidine
isoforms and its eventual decomposition products. Our results
indicate that the erythro-magneto-HA virosomes may protect the
5-Aza-2-dC from rapid and premature decomposition thus leading
to an improvement of half-life of therapeutic compound.
Moreover, data from FACS analysis indicate that the total
amount of this anti-cancer drug necessary to obtain growth arrest
and apoptotic response in tumor cells is approximately 10 times
less when erythro-magneto-HA virosome delivery system is used,
compared to standard therapy suggesting that the erythro-
magneto-HA virosomes highly increase the bioavailability of the
drug. Furthermore, toxicity is observed at earlier times when the
drug was encapsulated into erythro-magneto-HA virosomes.
Conclusion
In conclusion we report here a novel erythrocyte-based drug
delivery system, the erythro-magneto-HA virosomes, which
present many potential advantages that enable it to be used in
certain situations as an alternative to other drug delivery systems.
This advantages include: enhancing the bioavailability of drugs
through its high fusogenic capability with target cells; the potential
for magnetically driving the virosomes to desired sites of action; its
potential for protecting therapeutics from degradation or elimina-
tion prior to reaching target tissues or organs; its high
biocompatibility relative to other carrier systems which may be
optimized by employing autologous erythrocytes. Finally, the
composition of this erythrocyte-based drug delivery system make it
applicable to many clinical settings, such as neoplastic and
cardiovascular diseases, pathologies caused by the infection of a
human or animal virus and certain metabolic diseases.
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